Brentuximab vedotin, an antibody-drug conjugates targeting CD30, has been approved by FDA for treatment of relapsed/refractory Hodgkin lymphoma and anaplastic large cell lymphoma [27]–[28]. This evidence concerns the gene TNFRSF8 and anaplastic large cell lymphoma.